Medical Devices
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global medical device regulatory pathways, market trends, and innovation impacting pharmaceutical R&D and commercialization.
Showing 1–12 of 19 articles
Quick answer
NovaPharmaNews Medical Devices hub for NMPA covers 19 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours
PMDA Approves New Pharmaceuticals and Medical Devices: What's New
Stryker Australia Receives TGA Approval for Total Temporomandibular Joint Prosthesis
Australia's TGA Section 41HD Emergency Medical Device Import Approvals: Complete Guide for Healthcare Providers
Vector Science & Therapeutics Files Patent for Microneedle Catheter Platform for Cancer Drug Delivery
NAMSA and Lexitas Form Strategic Partnership for Comprehensive Ophthalmic Medical Device Development Services
TGA Issues Guidance on Combination and Boundary Products for Pharmaceutical Companies in APAC
Thailand Emerges as ASEAN Medical Device Gateway as Market Set to Reach $18.6B by 2029
TGA Updates Comprehensive Regulatory Framework for Implantable Medical Devices in Australia
Akso Health Group Launches Brain-Computer Interface R&D Program Targeting Neurotechnology Market
Australia's TGA Updates Personalised Medical Device Regulations: New Guidance for Market Authorization and Supply Chain Compliance
Quasar Medical Opens New Thailand Manufacturing Facility to Expand MedTech Production Capacity
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.